Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL439830 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL27663032 | 1.00 | CA5A (0.60) | CA5ACA5BALDH1A1CYP3A4HPGD | |
| Sulfuric Acid SCHEMBL29195407 | 1.00 | CA5A (0.60) | CA5ACA5BALDH1A1CYP3A4HPGD | |
| Sulfuric Acid SCHEMBL28595295 | 0.95 | — | — | |
| Sulfuric Acid SCHEMBL10449162 | 0.95 | CA5A (0.55) | CA5ACA5BALDH1A1CYP3A4HPGD | |
| Sulfuric Acid SCHEMBL16343930 | 0.95 | — | — | |
| Sulfuric Acid SCHEMBL28181522 | 0.95 | — | — | |
| Sulfuric Acid SCHEMBL21625744 | 0.95 | CA5A (0.55) | CA5ACA5BALDH1A1CYP3A4HPGD | |
| Sulfuric Acid SCHEMBL28339349 | 0.95 | — | — | |
| Sulfuric Acid SCHEMBL27740934 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | WILLIAM M YARBROUGH FOUND (US) | 2026-02-26 | — | — | US | claimed |
| US-12310939-B2 | Method for treating rheumatoid arthritis | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-05-27 | — | — | US | claimed |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUND (US) | 2025-05-22 | — | — | US | claimed |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-03-04 | — | — | US | claimed |
| US-12178795-B2 | Method for treating metastatic prostate cancer | THE WILLIAM YARBROUGH FOUNDATION (US) | 2024-12-31 | — | — | US | claimed |
| US-12041932-B2 | Antimicrobial compositions | MELZER CHEMICALS PVT. LTD. (IN) | 2024-07-23 | — | — | US | claimed |
| WO-2023214421-A1 | ANTIMICROBIAL COMPOSITIONS | MELZER CHEMICALS PVT. LTD. (IN) | 2023-11-09 | — | — | WO | claimed |
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-10-26 | — | — | US | claimed |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-24 | — | — | US | claimed |
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | THE WILLIAM M YARBROUGH FOUNDATION | 2023-08-17 | — | — | US | claimed |
| EP-1940949-A1 | TEMPORARY WET STRENGTH RESIN FOR PAPER APPLICATIONS | Kemira OYJ (FI) | 2008-07-09 | — | — | EP | claimed |
| WO-2007041380-A1 | TEMPORARY WET STRENGTH RESIN FOR PAPER APPLICATIONS | KEMIRA OYJ (FI) | 2007-04-12 | — | — | WO | claimed |
| EP-1023497-A1 | SOFT TISSUE PAPER HAVING A SOFTENING COMPOSITION CONTAINING AN ELECTROLYTE DEPOSITED THEREON | THE PROCTER & GAMBLE COMPANY (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1999016974-A1 | SOFT TISSUE PAPER HAVING A SOFTENING COMPOSITION CONTAINING AN ELECTROLYTE DEPOSITED THEREON | THE PROCTER & GAMBLE COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| EP-0313978-B1 | STABILIZERS FOR STAINING SOLUTIONS | MERCK PATENT GmbH (DE) | 1992-04-15 | — | — | EP | claimed |
| US-4933164-A | Stabilizers for staining solutions | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-06-12 | — | — | US | claimed |
| EP-0220438-B1 | STABILIZER FOR STAINING SOLUTIONS | MERCK PATENT GmbH (DE) | 1989-05-31 | — | — | EP | claimed |
| EP-0313978-A2 | Stabilizers for staining solutions | MERCK PATENT GmbH (DE) | 1989-05-03 | — | — | EP | claimed |
| US-4687489-A | DIMETHYLAMMONIUM SULFATE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-08-18 | — | — | US | claimed |
| EP-0220438-A2 | Stabilizer for staining solutions | MERCK PATENT GmbH (DE) | 1987-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | ALK, C9, MSR1 | CA5A 2539/4885CA5B 2732/4885ALDH1A1 1514/4885 |
| US-12178795-B2 | Method for treating metastatic prostate cancer | BPHL, KLK3, ACP3 | CA5A 455/4885CA5B 449/4885ALDH1A1 572/4885 |
| US-12239626-B2 | Method for treating infectious diseases with isothiocyanate functional compounds | CFTR, TST, ICMT | CA5A 3493/4885CA5B 2780/4885ALDH1A1 1558/4885 |
| US-12310939-B2 | Method for treating rheumatoid arthritis | MIF, TNF, MMP12 | CA5A 2430/4885CA5B 1795/4885ALDH1A1 758/4885 |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | TST, TMSB10, NHERF1 | CA5A 1908/4885CA5B 1515/4885ALDH1A1 3056/4885 |
| US-20230338324-A1 | METHOD FOR TREATING RHEUMATOID ARTHRITIS | MIF, TNF, MMP12 | CA5A 2407/4885CA5B 1732/4885ALDH1A1 990/4885 |
| US-20230263763-A1 | METHOD FOR TREATING INFECTIOUS DISEASES WITH ISOTHIOCYANATE FUNCTIONAL COMPOUNDS | CFTR, TST, ICMT | CA5A 3493/4885CA5B 2780/4885ALDH1A1 1558/4885 |
| US-20230255920-A1 | METHOD FOR TREATING METASTATIC PROSTATE CANCER | BPHL, KLK3, ACP3 | CA5A 455/4885CA5B 449/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.